• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

38th Annual Meeting of the Society for Immunotherapy of Cancer – SITC (San Diego, Nov 3-5)

September 27, 2023 By Caroline Lonez

We are thrilled to announce we will share five poster presentations with updated results from our different platforms at SITC from November 3-5, 2023 in San Diego!

Posters presented on Friday, Nov 3:

  • Abstract 231: Differential effects of target ligands and receptor architecture upon NKG2D CAR T cell activation
  • Abstract 285: Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer and optimize CAR T-cell functionality
  • Abstract 297: Improvement of CAR T-cell performance by simultaneous downregulation of multiple co-inhibitory receptors

Posters presented on Saturday, Nov 4:

  • Abstract 232: NKG2D-based multi-specific CAR T-cells to overcome antigen escape and improve anti-tumor efficacy
  • Abstract 298: A miRNA-based shRNA platform for the easy, safe, and effective generation of allogeneic CAR T-cells

See you there!!

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use